These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

306 related articles for article (PubMed ID: 18650155)

  • 1. Basal breast cancer molecular subtype predicts for lower incidence of axillary lymph node metastases in primary breast cancer.
    Crabb SJ; Cheang MC; Leung S; Immonen T; Nielsen TO; Huntsman DD; Bajdik CD; Chia SK
    Clin Breast Cancer; 2008 Jun; 8(3):249-56. PubMed ID: 18650155
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biomarker expression and St Gallen molecular subtype classification in primary tumours, synchronous lymph node metastases and asynchronous relapses in primary breast cancer patients with 10 years' follow-up.
    Falck AK; Bendahl PO; Chebil G; Olsson H; Fernö M; Rydén L
    Breast Cancer Res Treat; 2013 Jul; 140(1):93-104. PubMed ID: 23807420
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Axillary lymph node status of operable breast cancers by combined steroid receptor and HER-2 status: triple positive tumours are more likely lymph node positive.
    Van Calster B; Vanden Bempt I; Drijkoningen M; Pochet N; Cheng J; Van Huffel S; Hendrickx W; Decock J; Huang HJ; Leunen K; Amant F; Berteloot P; Paridaens R; Wildiers H; Van Limbergen E; Weltens C; Timmerman D; Van Gorp T; Smeets A; Van den Bogaert W; Vergote I; Christiaens MR; Neven P
    Breast Cancer Res Treat; 2009 Jan; 113(1):181-7. PubMed ID: 18264760
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Human epidermal growth factor receptor 2 status correlates with lymph node involvement in patients with estrogen receptor (ER) negative, but with grade in those with ER-positive early-stage breast cancer suitable for cytotoxic chemotherapy.
    Bartlett JM; Ellis IO; Dowsett M; Mallon EA; Cameron DA; Johnston S; Hall E; A'Hern R; Peckitt C; Bliss JM; Johnson L; Barrett-Lee P; Ellis P
    J Clin Oncol; 2007 Oct; 25(28):4423-30. PubMed ID: 17906205
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The association between biological subtype and isolated regional nodal failure after breast-conserving therapy.
    Wo JY; Taghian AG; Nguyen PL; Raad RA; Sreedhara M; Bellon JR; Wong JS; Gadd MA; Smith BL; Harris JR
    Int J Radiat Oncol Biol Phys; 2010 May; 77(1):188-96. PubMed ID: 20171798
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prediction of axillary lymph node status of breast cancer patients by tumorbiological factors of the primary tumor.
    Fehm T; Maul H; Gebauer S; Scharf A; Baier P; Sohn C; Jäger W; Gebauer G
    Strahlenther Onkol; 2005 Sep; 181(9):580-6. PubMed ID: 16170485
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Breast cancer subtypes as defined by the estrogen receptor (ER), progesterone receptor (PR), and the human epidermal growth factor receptor 2 (HER2) among women with invasive breast cancer in California, 1999-2004.
    Parise CA; Bauer KR; Brown MM; Caggiano V
    Breast J; 2009; 15(6):593-602. PubMed ID: 19764994
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Can we identify the group of small invasive (T1a,b) breast cancers with minimal risk of axillary lymph node involvement? A pathohistological and DNA flow cytometric study.
    Bezić J; Samija-Projić I; Projić P; Ljubković J; Capkun V; Tomić S
    Pathol Res Pract; 2011 Jul; 207(7):438-42. PubMed ID: 21689895
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predictors of axillary lymph node metastases in women with early breast cancer in Singapore.
    Tan LG; Tan YY; Heng D; Chan MY
    Singapore Med J; 2005 Dec; 46(12):693-7. PubMed ID: 16308642
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes.
    Carey LA; Dees EC; Sawyer L; Gatti L; Moore DT; Collichio F; Ollila DW; Sartor CI; Graham ML; Perou CM
    Clin Cancer Res; 2007 Apr; 13(8):2329-34. PubMed ID: 17438091
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predictors of axillary lymph node metastases in patients with T1 breast carcinoma.
    Barth A; Craig PH; Silverstein MJ
    Cancer; 1997 May; 79(10):1918-22. PubMed ID: 9149018
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Breast cancer subtype approximations and loco-regional recurrence after immediate breast reconstruction.
    Kneubil MC; Brollo J; Botteri E; Curigliano G; Rotmensz N; Goldhirsch A; Lohsiriwat V; Manconi A; Martella S; Santillo B; Petit JY; Rietjens M
    Eur J Surg Oncol; 2013 Mar; 39(3):260-5. PubMed ID: 23313014
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Can sentinel lymph node biopsy be omitted in patients with favorable breast cancer histology?
    Mendez JE; Fey JV; Cody H; Borgen PI; Sclafani LM
    Ann Surg Oncol; 2005 Jan; 12(1):24-8. PubMed ID: 15827774
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Presenting features of breast cancer differ by molecular subtype.
    Wiechmann L; Sampson M; Stempel M; Jacks LM; Patil SM; King T; Morrow M
    Ann Surg Oncol; 2009 Oct; 16(10):2705-10. PubMed ID: 19593632
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characteristics and outcomes according to molecular subtypes of breast cancer as classified by a panel of four biomarkers using immunohistochemistry.
    Park S; Koo JS; Kim MS; Park HS; Lee JS; Lee JS; Kim SI; Park BW
    Breast; 2012 Feb; 21(1):50-7. PubMed ID: 21865043
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognosis in women with small (T1mic,T1a,T1b) node-negative operable breast cancer by immunohistochemically selected subtypes.
    Cancello G; Maisonneuve P; Rotmensz N; Viale G; Mastropasqua MG; Pruneri G; Montagna E; Dellapasqua S; Iorfida M; Cardillo A; Veronesi P; Luini A; Intra M; Gentilini O; Scarano E; Goldhirsch A; Colleoni M
    Breast Cancer Res Treat; 2011 Jun; 127(3):713-20. PubMed ID: 21452022
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Estrogen receptor, progesterone receptor, HER-2, and response to postmastectomy radiotherapy in high-risk breast cancer: the Danish Breast Cancer Cooperative Group.
    Kyndi M; Sørensen FB; Knudsen H; Overgaard M; Nielsen HM; Overgaard J;
    J Clin Oncol; 2008 Mar; 26(9):1419-26. PubMed ID: 18285604
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Clinical characteristics and survival in the operable breast cancer patients with different molecular subtypes].
    Zhang HM; Zhang BN; Xuan LX; Zhao P
    Zhonghua Zhong Liu Za Zhi; 2009 Jun; 31(6):447-51. PubMed ID: 19950556
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinicopathologic significance of the basal-like subtype of breast cancer: a comparison with hormone receptor and Her2/neu-overexpressing phenotypes.
    Kim MJ; Ro JY; Ahn SH; Kim HH; Kim SB; Gong G
    Hum Pathol; 2006 Sep; 37(9):1217-26. PubMed ID: 16938528
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lobular and non-lobular breast cancers differ regarding axillary lymph node metastasis: a cross-sectional study on 4,292 consecutive patients.
    Vandorpe T; Smeets A; Van Calster B; Van Hoorde K; Leunen K; Amant F; Moerman P; Deraedt K; Brouckaert O; Van Huffel S; Wildiers H; Christiaens MR; Neven P
    Breast Cancer Res Treat; 2011 Jul; 128(2):429-35. PubMed ID: 21562708
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.